FTC and bloggers: media guide to new rules

The Web has erupted with news, opinion and practical guidance on the new FTC rules that apply to disclosures on blogger freebies. As a public service, NutriSupLaw offers a sampling of the best of initial analysis.

There’s gold in them thar pills, and in the companies that sell them

Despite the recession, nutritional supplement companies remain popular with consumers and Wall Street. A $35 million merger and $132 million IPO are the latest examples of industry’s financial health.

To friend or not to friend? That is the FDA question

How closely can nutritional supplement companies connect with the fast-moving world of social media? The FDA will address these questions at a hearing Nov. 12-13 in Washington. The agency is soliciting comments in the Federal Register.

Orlistat and Hydroxycut: Similar health problems, but comparable FDA treatment?

This is a tale of two types of weight-loss products and how the Food and Drug Administration had different responses to similar problems with them. The separate, but not equivalent treatment raises questions about how the FDA operates.

How to get off the FDA blacklist

GUEST POST by Jennifer Diaz The United States Food and Drug Administration (FDA) has authority to put an importer, manufacturer, shipper, grower, geographic area of a country, or an entire country on a “detention without physical examination” (DWPE) list  (a/k/a the FDA’s ‘Black List’).  To check if a company you are doing business with is [...]

Placebos cloud results of clinical trials, medical practice

Placebos seem to make a difference in research and clinical practice. For that reason, testimonials and open-label trial results should never be provided as sole evidence of efficacy when a product marketing campaign is challenged by a regulatory authority.